8-K: Aquestive Anaphylm Faces FDA Setback on Packaging, Admin

Aquestive Therapeutics received a Complete Response Letter from the FDA for Anaphylm, citing deficiencies in packaging and administration, but expects rapid resolution and Q3 2026 resubmission.

Summary

• The U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) on January 30, 2026, for Aquestive Therapeutics' New Drug Application (NDA) seeking approval of Anaphylm (dibutepinephrine) Sublingual Film.
• Deficiencies cited in the CRL were limited to packaging and administration, specifically issues identified in the Anaphylm human factors (HF) validation study, such as difficulty opening the pouch and incorrect film placement.
• The FDA also requested a single pharmacokinetics (PK) study to understand the impact of any modifications to packaging and labeling.
• Aquestive Therapeutics believes it can rapidly resolve these deficiencies by modifying the pouch opening, instructions for use, and labeling, and plans to conduct new HF and PK studies in parallel.
• The company estimates resubmission of the NDA in Q3 2026, assuming completion of the required studies and typical FDA response times, and intends to request rapid review.
• No CMC (Chemistry, Manufacturing, and Controls) issues or questions regarding comparability data (bracketing, repeat dose, sustainability) were noted in the CRL.
• Aquestive is continuing its global strategy for Anaphylm, having initiated regulatory engagements in Canada, Europe, and the United Kingdom in 2025.
• The company received positive feedback from the European Medicines Agency (EMA) that no further clinical trials are needed prior to regulatory approval submission in Europe.
• Aquestive expects to submit marketing authorization applications in Europe and Canada in the second half of 2026.
• The company remains well-capitalized and anticipates ending 2026 with significant cash, believing it has sufficient funding to complete the Anaphylm approval and pre-launch processes in the U.S. and progress in other key markets.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a significant setback due to the CRL, delaying a critical product launch. While the issues are addressable, the delay introduces uncertainty and extends the time to market for a potentially transformative product.

Positives

• FDA deficiencies were limited to packaging and administration, not the efficacy or safety of Anaphylm.
• No CMC issues or questions on comparability data (bracketing, repeat dose, sustainability) were noted in the CRL.
• Aquestive Therapeutics believes it can rapidly resolve the identified deficiencies and expects to resubmit the NDA as early as Q3 2026, with a request for rapid review.
• The company received positive feedback from the European Medicines Agency (EMA) indicating no further clinical trials are needed for European regulatory submission.
• Aquestive remains well-capitalized and anticipates ending 2026 with significant cash, with sufficient funding for Anaphylm's approval and pre-launch in the U.S. and progression in other key markets.
• Anaphylm's comprehensive clinical development program demonstrated a PK profile comparable to leading epinephrine auto-injectors and a similar safety profile to epinephrine.

Negatives

• Received a Complete Response Letter (CRL) from the FDA, meaning the New Drug Application (NDA) for Anaphylm cannot be approved in its current form.
• The CRL cited deficiencies in the human factors (HF) validation study, including difficulty opening the pouch and incorrect film placement, which the FDA believes could cause significant safety issues.
• The FDA requested a new HF validation study and a single pharmacokinetics (PK) study to address the identified issues and understand the impact of modifications.
• The need for additional studies and modifications will delay the potential approval, pushing the NDA resubmission to Q3 2026.
• Potential tolerability issues (e.g., chewing film, taste) were noted by some participants in the HF study, requiring further analysis.

Risks

• Risk of delays or changes to the timing, cost, and success of product development activities and clinical trials for Anaphylm.
• Risk of delays in the regulatory approval process through the FDA for Anaphylm, or failure to receive FDA approval at all.
• Risk of FDA inspections of manufacturing and clinical study sites for Anaphylm.
• Risk of government shutdowns or actions to reduce government workforces impacting the FDA's ability to act on product approvals.
• Risk of the company's ability to generate sufficient clinical and other human factor data, including pharmacokinetic and pharmacodynamic (PK/PD) comparability data.
• Risks associated with the company's ability to address the FDA's comments and identified deficiencies in the NDA, including those raised in the CRL.
• Risk that the FDA may consider issues raised in the citizen petition submitted regarding Anaphylm on October 1, 2025.
• Risks associated with the success of any competing products, including generics.
• Risks and uncertainties inherent in commercializing a new product, including technology, financial, market, implementation risks, and regulatory limitations.
• Risk of development of a sales and marketing capability for commercialization of Anaphylm, if approved.
• Risks associated with the potential impact on the value of the company of the sale or outlicensing of products and product candidates.
• Risk of insufficient capital and cash resources, including access to debt and equity financing, and revenues from operations, to satisfy liquidity and cash requirements and fund future activities.
• Risk of the impact of obligations under the Purchase Agreement and Royalty Rights Agreement on the ability to fund operations and pay debt, and to refinance 13.5% Senior Secured Notes.
• Risk that manufacturing capabilities will be insufficient to support demand for Anaphylm in the U.S. and abroad, if approved.
• Risk of eroding market share for Suboxone, which accounts for a substantial part of current operating revenue.
• Risk of default of debt instruments.
• Risks related to the outsourcing of certain sales, marketing, and other operational functions to third parties.
• Risk of the rate and degree of market acceptance in the U.S. and abroad of Anaphylm, if approved.
• Risk associated with the size and growth of product markets.
• Risk associated with compliance with all FDA and other governmental and customer requirements for manufacturing facilities.
• Risks associated with intellectual property rights and infringement claims relating to products, and timely issuance of patents.
• Risk of unexpected patent developments.
• Risk of legislation and regulatory actions and changes in laws or regulations affecting the business, including product pricing, reimbursement, or access.
• Risk of loss of significant customers.
• Risks related to claims and legal proceedings against the company, including patent infringement, securities, business torts, investigative, product safety or efficacy, and antitrust litigation matters.
• Risk of product recalls and withdrawals.
• Risks related to any disruptions in information technology networks and systems, including cybersecurity attacks.
• Risk of increased cybersecurity attacks and data accessibility disruptions due to remote working arrangements.
• Risk of adverse developments affecting the financial services industry, inflation, and changing interest rates.
• Risks related to the impact of pandemic diseases on the business.
• Risks and uncertainties related to general economic, political (including the Ukraine and Israel wars and other acts of war and terrorism), business, industry, regulatory, financial, and market conditions.
• Risks related to uncertainty about presidential administration initiatives and their impact on the business, including imposition of government tariffs and other trade restrictions.

Future Outlook

Aquestive Therapeutics plans to rapidly address FDA's packaging and administration concerns for Anaphylm, aiming for a Q3 2026 resubmission with a request for rapid review. The company also expects to submit marketing authorization applications for Anaphylm in Canada and Europe in the second half of 2026, following positive feedback from the EMA. They anticipate ending 2026 with significant cash and believe they have sufficient funding for Anaphylm's approval and pre-launch in the U.S. and progression in other key markets.

Management Comments

• Daniel Barber, President and CEO: "While it is unfortunate to have received a CRL, we believe that, with the clarity we now have from the FDA, we have made significant progress toward approval. We are encouraged that the issues in the letter are limited to human factors and a supportive PK study, once human factors are addressed, and we noted several labeling comments that will inform the final label for Anaphylm, if approved by the FDA."
• Daniel Barber, President and CEO: "We remain confident in the effectiveness and safety of Anaphylm and its potential as an easy-to-use, easy-to-carry, fast-acting epinephrine treatment. We look forward to working with the FDA to achieve approval for Anaphylm. Our commitment to bringing this innovative therapy to the allergy community remains steadfast."
• Allergist Jay Lieberman, M.D., Professor at the University of Tennessee Health Science Center: "As a clinician and investigator for various allergy clinical trials, I am well versed in the nuances related to clinical development and regulatory approval. FDAs response is focused on patient experience issues and their potential impacts. I am confident in Aquestives ability to address the issues described above and remain optimistic in having Anaphylm available for my patients in the future. Given the continued underuse of epinephrine in anaphylaxis, the availability of more treatment options remains a top priority for clinicians and the allergy community."

Industry Context

StockSavvy.ai notes that the delay in FDA approval for Anaphylm, while focused on packaging and administration, highlights the stringent regulatory hurdles for novel drug delivery systems, especially for life-saving medications like epinephrine. The continued underuse of epinephrine in anaphylaxis, as noted by Dr. Lieberman, underscores the significant unmet need for more accessible and user-friendly treatment options, which Anaphylm aims to address. The company's global expansion strategy, particularly positive feedback from the EMA, suggests a broader market opportunity even with U.S. delays.

Comparison to Industry Standards

• Anaphylm's median time to open the 1st dose pouch (17 seconds) and 2nd dose (8 seconds) compares favorably to epinephrine medical device data.
• Aquestive's approved film product complaint database includes only 1 product complaint related to potential tearing of a strip when opening a pouch out of approximately 2.5 billion doses shipped, indicating a strong track record for film products.
• Anaphylm's clinical development program demonstrated a PK profile comparable to the leading epinephrine auto-injectors.

Legal Proceedings

• Risk that the FDA may consider issues raised in the citizen petition submitted to the FDA regarding Anaphylm on October 1, 2025.
• Risks related to claims and legal proceedings against the company including patent infringement, securities, business torts, investigative, product safety or efficacy and antitrust litigation matters.

Stakeholder Impact

• Shareholders: Potential negative impact due to delayed approval and commercialization of Anaphylm, which could affect future revenue and stock price. Increased R&D expenses for additional studies.
• Patients (allergy community): Delayed access to a potentially innovative, non-invasive epinephrine treatment option for severe allergic reactions.
• Employees: Continued focus on resolving regulatory issues and advancing global strategy.
• Regulatory Authorities (FDA, EMA, Health Canada, MHRA): Ongoing engagement and review processes for Anaphylm.

Next Steps

• Request a Type A meeting with the FDA to discuss the most efficient path forward for resubmission.
• Modify the pouch opening, instructions for use, pouch and carton labeling for Anaphylm.
• Conduct a new human factors (HF) validation study with the modified packaging and instructions.
• Conduct a single pharmacokinetics (PK) study as requested by the FDA.
• Resubmit the New Drug Application (NDA) for Anaphylm in Q3 2026, requesting rapid review.
• Submit a marketing authorization application for Anaphylm in Europe in the second half of 2026.
• Submit a New Drug Submission (NDS) for Anaphylm in Canada in the second half of 2026.
• Receive feedback from the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom in Q1 2026.
• Commence principal payments on 13.5% Senior Secured Notes in 2026.

Key Dates

Recommendation

While the FDA's Complete Response Letter is a setback, the issues cited are limited to packaging and administration, not the drug's efficacy or safety. The company's plan for rapid resolution and Q3 2026 resubmission, coupled with positive international regulatory progress and a strong cash position, suggests a path forward. However, the delay and additional studies introduce uncertainty. A "hold" recommendation allows investors to monitor the progress of the resubmission and subsequent FDA decision without exiting a potentially valuable long-term asset.

Keywords

Anaphylm, dibutepinephrine, Sublingual Film, FDA, Complete Response Letter, CRL, NDA, anaphylaxis, epinephrine, Aquestive Therapeutics, pharmaceutical, drug approval, human factors study, pharmacokinetics study, regulatory approval, allergy treatment, biotech